Market revenue in 2023 | USD 84.4 million |
Market revenue in 2030 | USD 164.9 million |
Growth rate | 10% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67.06% in 2023. Horizon Databook has segmented the Thailand large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
The CDMO market in Thailand is growing at a rapid rate due to increase in outsourcing services by pharmaceutical companies amid a growing pharmaceutical industry.
The country’s increasing population is one of the major reasons driving its CDMO market. The Journal of Health Science reports that national spending on biologics has increased significantly from USD 547.0 million (16,513.0 million Thai baht) in 2009 to USD 1,664.0 million (50,182.0 million Thai baht) in 2018.
This is based on the data from the Thai Food and Drug Administration (Thai FDA). The majority of the biological goods used in Thailand are imported (96.0%), making Thailand a major importer in the overall global biological market.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Thailand large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account